LONG-TERM FOLLOW-UP STUDY OF PATIENTS WITH SPINAL MUSCULAR ATROPHY RECEIVING RISDIPLAM TREATMENT

Go Back to All Clinical Trials

LONG-TERM FOLLOW-UP STUDY OF PATIENTS WITH SPINAL MUSCULAR ATROPHY RECEIVING RISDIPLAM TREATMENT

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

Conditions:
Spinal Muscular Atrophy
Age: Between 1 Year(s) - 100 Year(s)
Gender: Male or Female

Other Inclusion Criteria:
1. Able to provide informed consent or assent when appropriate, as determined by the patient's age and individual site and local standards.
2. Previously confirmed diagnosis of 5q-AR SMA.
3. Prescribed or continued risdiplam based on clinical judgment of prescriber after August 7, 2020.

You may not be eligible for this study if the following are true:

1. Hypersensitivity to risdiplam.
2. Participated in a registrational trial for risdiplam.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Clinical Research Studies